Incyte Corp (INCY)

$86.85 +0.57 (0.66%)
Market Cap 16.85B
Revenue (ttm) 4.24B
Net Income (ttm) 32.61M
EPS (ttm) N/A
PE Ratio 21.57
Forward PE 16.90
Profit Margin 0.77%
Debt to Equity Ratio 0.00
Volume 1,303,800
Avg Vol 1,821,552
Day's Range N/A - N/A
Shares Out 195.28M
Stochastic %K 76%
Beta 0.73
Analysts Sell
Price Target $84.52

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
SweepCastApp
SweepCastApp Oct. 4 at 8:26 AM
$INCY: Unusual Options Activity Alerted CALL flow observed 35x contracts at Strike price of $77.5 Exp on 11/21/2025 with Premium of $37K and showing NEUTRAL Sentiment
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 3:22 PM
Enter: $INCY NOV 21 2025 $88 CALLS Buy in Price: $3.62 - $6.10 Take Profit: $5.10 Stop Bleeding: $3.19 ROI Potential: 41% Exit Within: 340 Minutes https://moneygroup.us/alerts
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 2 at 7:23 PM
🏛️ 🚀 $INCY up ⬆️7.52% since our entry $82.46 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 1 at 11:08 PM
$INCY Share Price: $86.69 Contract Selected: Jan 16, 2026 $90 Calls Buy Zone: $4.33 – $5.35 Target Zone: $7.76 – $9.49 Potential Upside: 69% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Oct. 1 at 8:17 PM
Selective boy has mentioned 4 names in 2025 with the 5th one yesterday $EXEL $NKTR $ABCL $UTHR $INCY i think im content with these 5
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 1 at 1:45 PM
🎯 Target Hit 🏁 📨 Signal From Sep 26, 2025 🏛️ $INCY 💵 Entry: $82.4600 ✅ Exit: $85.4286 💰 P/L: +3.60% 👉 Free Trial! Check bio.
0 · Reply
highnihilism
highnihilism Sep. 30 at 11:12 AM
$MAIN Main Street Capital: 115 trades, $941K vs $111K avg (8.49x !!!). $24K calls / $917K puts. $INCY Incyte: 30 trades, $26K vs $200K avg (0.13x !!!!). $24K calls / $2K puts. $NUVB Nuvation Bio: 73 trades, $87K vs $95K avg (0.92x). $24K calls / $63K puts. $RGEN Repligen: 33 trades, $44K vs $139K avg (0.32x). $24K calls / $20K puts.
0 · Reply
highnihilism
highnihilism Sep. 29 at 6:28 PM
S&P MidCap 400 (Health Care) → $INCY Incyte $JAZZ Jazz Pharmaceuticals $LH Laboratory Corp. of America $MD Mednax $MOH Molina Healthcare
0 · Reply
2_logs_higher
2_logs_higher Sep. 29 at 4:04 PM
$AGEN & $INCY remembering when INCY bought into both Agen and Merus. Agen sure could use a USA based MOAD.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 29 at 3:43 AM
Enter: $INCY NOV 21 2025 $88 CALLS Buy in Price: $3.62 - $4.90 Take Profit: $4.96 Stop Bleeding: $3.19 ROI Potential: 37% Exit Within: 95 Minutes https://moneygroup.us/alerts
0 · Reply
Latest News on INCY
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Sep 28, 2025, 12:20 AM EDT - 6 days ago

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 24, 2025, 4:30 PM EDT - 10 days ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cramer reveals 5 undervalued stocks that are must-own heading into 2026

Sep 24, 2025, 3:15 PM EDT - 10 days ago

Cramer reveals 5 undervalued stocks that are must-own heading into 2026

AXP CAT DLTR TMUS

Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher

Sep 22, 2025, 6:46 PM EDT - 12 days ago

Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher

DELL DLTR EXPE TMUS APO AXP BXP

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

Sep 22, 2025, 7:30 AM EDT - 12 days ago

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 15 days ago

3 Potential Biotech Acquisition Targets

AZN ETNB MLYS SNDX TVTX

US FDA approves Incyte's eczema treatment for pediatric patients

Sep 18, 2025, 4:29 PM EDT - 16 days ago

US FDA approves Incyte's eczema treatment for pediatric patients

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Sep 18, 2025, 4:21 PM EDT - 16 days ago

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Sep 17, 2025, 1:00 AM EDT - 17 days ago

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

Sep 10, 2025, 7:30 AM EDT - 24 days ago

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 25 days ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

CRSP XBI XLV

Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 1:46 PM EDT - 25 days ago

Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 4:13 PM EDT - 4 weeks ago

Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 11:38 AM EDT - 4 weeks ago

Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Sep 3, 2025, 9:15 AM EDT - 4 weeks ago

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio

Aug 30, 2025, 9:30 AM EDT - 5 weeks ago

Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

Aug 25, 2025, 8:00 AM EDT - 5 weeks ago

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

Incyte to Present at Upcoming Investor Conferences

Aug 19, 2025, 8:00 AM EDT - 6 weeks ago

Incyte to Present at Upcoming Investor Conferences

20 stocks in the S&P 500 that are high achievers this earnings season

Aug 15, 2025, 8:52 AM EDT - 7 weeks ago

20 stocks in the S&P 500 that are high achievers this earnings season

ANET APH COIN CTRA EQT EXE FICO

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 2 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 2 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Jul 31, 2025, 4:30 PM EDT - 2 months ago

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 1:33 PM EDT - 2 months ago

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Jul 29, 2025, 11:13 AM EDT - 2 months ago

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Jul 29, 2025, 8:30 AM EDT - 2 months ago

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Jul 29, 2025, 7:00 AM EDT - 2 months ago

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Jul 24, 2025, 5:02 PM EDT - 2 months ago

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Incyte to Report Second Quarter Financial Results

Jul 10, 2025, 8:00 AM EDT - 3 months ago

Incyte to Report Second Quarter Financial Results

Incyte: New CEO Brings A New Possible Outcome

Jul 3, 2025, 6:11 AM EDT - 3 months ago

Incyte: New CEO Brings A New Possible Outcome

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Jun 26, 2025, 7:30 AM EDT - 3 months ago

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Incyte Says FDA Extended Review Period for Opzelura

Jun 20, 2025, 5:10 PM EDT - 3 months ago

Incyte Says FDA Extended Review Period for Opzelura

Incyte Lymphoma Treatment Gets FDA Approval

Jun 18, 2025, 4:12 PM EDT - 3 months ago

Incyte Lymphoma Treatment Gets FDA Approval

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Jun 18, 2025, 3:39 PM EDT - 3 months ago

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Jun 15, 2025, 4:00 AM EDT - 3 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QGEN

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Jun 15, 2025, 3:15 AM EDT - 3 months ago

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Jun 12, 2025, 6:45 PM EDT - 4 months ago

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2025, 4:30 PM EDT - 4 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Jun 3, 2025, 10:30 AM EDT - 4 months ago

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

Jun 2, 2025, 12:15 PM EDT - 4 months ago

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

AIG APTV BALL CTRA DELL DVA ELV

Incyte to Present at Upcoming Investor Conference

May 27, 2025, 8:00 AM EDT - 4 months ago

Incyte to Present at Upcoming Investor Conference

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

May 15, 2025, 2:30 PM EDT - 5 months ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

20 stocks of companies showing excellent earnings-season trends even as the economy cools

May 12, 2025, 11:18 AM EDT - 5 months ago

20 stocks of companies showing excellent earnings-season trends even as the economy cools

AMD APH CF CTRA DVN ENPH EQT

Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:53 PM EDT - 5 months ago

Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript

Incyte raises 2025 sales forecast for blood cancer drug after solid quarter

Apr 29, 2025, 9:03 AM EDT - 5 months ago

Incyte raises 2025 sales forecast for blood cancer drug after solid quarter

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Apr 29, 2025, 7:00 AM EDT - 5 months ago

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 5 months ago

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 11:03 AM EDT - 5 months ago

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Incyte to Report First Quarter Financial Results

Apr 10, 2025, 8:00 AM EDT - 6 months ago

Incyte to Report First Quarter Financial Results

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

Mar 31, 2025, 5:02 PM EDT - 6 months ago

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

DAL BBY CCL CEG CZR DECK DXCM

SweepCastApp
SweepCastApp Oct. 4 at 8:26 AM
$INCY: Unusual Options Activity Alerted CALL flow observed 35x contracts at Strike price of $77.5 Exp on 11/21/2025 with Premium of $37K and showing NEUTRAL Sentiment
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 3:22 PM
Enter: $INCY NOV 21 2025 $88 CALLS Buy in Price: $3.62 - $6.10 Take Profit: $5.10 Stop Bleeding: $3.19 ROI Potential: 41% Exit Within: 340 Minutes https://moneygroup.us/alerts
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 2 at 7:23 PM
🏛️ 🚀 $INCY up ⬆️7.52% since our entry $82.46 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 1 at 11:08 PM
$INCY Share Price: $86.69 Contract Selected: Jan 16, 2026 $90 Calls Buy Zone: $4.33 – $5.35 Target Zone: $7.76 – $9.49 Potential Upside: 69% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Oct. 1 at 8:17 PM
Selective boy has mentioned 4 names in 2025 with the 5th one yesterday $EXEL $NKTR $ABCL $UTHR $INCY i think im content with these 5
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 1 at 1:45 PM
🎯 Target Hit 🏁 📨 Signal From Sep 26, 2025 🏛️ $INCY 💵 Entry: $82.4600 ✅ Exit: $85.4286 💰 P/L: +3.60% 👉 Free Trial! Check bio.
0 · Reply
highnihilism
highnihilism Sep. 30 at 11:12 AM
$MAIN Main Street Capital: 115 trades, $941K vs $111K avg (8.49x !!!). $24K calls / $917K puts. $INCY Incyte: 30 trades, $26K vs $200K avg (0.13x !!!!). $24K calls / $2K puts. $NUVB Nuvation Bio: 73 trades, $87K vs $95K avg (0.92x). $24K calls / $63K puts. $RGEN Repligen: 33 trades, $44K vs $139K avg (0.32x). $24K calls / $20K puts.
0 · Reply
highnihilism
highnihilism Sep. 29 at 6:28 PM
S&P MidCap 400 (Health Care) → $INCY Incyte $JAZZ Jazz Pharmaceuticals $LH Laboratory Corp. of America $MD Mednax $MOH Molina Healthcare
0 · Reply
2_logs_higher
2_logs_higher Sep. 29 at 4:04 PM
$AGEN & $INCY remembering when INCY bought into both Agen and Merus. Agen sure could use a USA based MOAD.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 29 at 3:43 AM
Enter: $INCY NOV 21 2025 $88 CALLS Buy in Price: $3.62 - $4.90 Take Profit: $4.96 Stop Bleeding: $3.19 ROI Potential: 37% Exit Within: 95 Minutes https://moneygroup.us/alerts
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 28 at 10:29 PM
$INCY China Medical System Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication The phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate AD in China met its primary endpoint, demonstrating that a significantly higher proportion of patients treated with ruxolitinib cream achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P<0.001).
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 26 at 2:33 PM
🚀 New Signal ✅ 🏛️ $INCY 🗓️ Sep 26, 2025 💵 Entry: $82.46 🎯 Target (Opt.): $85.43 (+3.60%) 👉 Check bio for full access
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 6:21 AM
$INCY: TRADE PUT flow found 100 @ 5.50, Strike 82.5, Exp 12/19/2025, Premium $55,000, Sentiment BULLISH
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 25 at 4:46 PM
Enter: $INCY OCT 17 2025 $85 CALLS Buy in Price: $2.60 - $2.65 Take Profit: $3.30 Stop Bleeding: $2.29 ROI Potential: 27% Exit Within: 169 Minutes https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Sep. 24 at 1:59 PM
RBC Capital has adjusted their stance on Incyte ( $INCY ), setting the rating to Sector Perform with a target price of 72 → 81.
0 · Reply
Nomorelies
Nomorelies Sep. 22 at 3:00 PM
$INCY
0 · Reply
pilobious
pilobious Sep. 22 at 2:04 AM
$INCY 5.48 million shares traded Friday. 3x normal volume. OE shenanigans.
1 · Reply
aaxaa
aaxaa Sep. 21 at 6:29 PM
$INCY
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 21 at 3:02 AM
Enter: $INCY OCT 17 2025 $88 CALLS Buy in Price: $2.41 - $4.30 Take Profit: $5.57 Stop Bleeding: $2.12 ROI Potential: 131% Exit Within: 182 Minutes https://moneygroup.us/alerts
0 · Reply
mananpat3l
mananpat3l Sep. 20 at 2:40 PM
$INCY
0 · Reply
Bornjever
Bornjever Sep. 19 at 6:17 PM
$INCY well the revenue will go third quarter for like a 1.3 billion and so we sell like 4.4-4.5 billion which is crazy with 85.00 per share???
0 · Reply
IN0V8
IN0V8 Sep. 19 at 4:20 PM
$INCY Buying Opportunity Jefferies raises target price to $102 from $90
0 · Reply